Vanda Pharmaceuticals Shares Jump 30% After FDA Approves Nereus for Motion Sickness
FDA has approved Vanda Pharmaceuticals' Nereus for the prevention of motion-induced vomiting, marking the first new treatment for the condition in over 40 years. The approval could expand Vanda’s market opportunity by addressing nausea associated with GLP-1 weight-loss therapies, driving a 30% jump in shares.
1. FDA Approval of Nereus
On January 2, 2026, the U.S. Food and Drug Administration granted approval to Vanda Pharmaceuticals’ Nereus for the prevention of motion-induced vomiting, marking the first new treatment for this indication in over four decades. The decision follows a Priority Review designation granted in August 2025, underscoring the regulator’s recognition of the unmet medical need for motion sickness therapies. Vanda’s submission was supported by the pivotal Voyager-1 Phase III trial, which enrolled 450 participants across 20 sites in the United States and demonstrated robust efficacy and a favorable safety profile compared to placebo.
2. Pivotal Trial Results and Safety Profile
In the Voyager-1 trial, Nereus achieved a 65% reduction in the incidence of vomiting episodes during a standardized sea-simulation challenge, compared to a 22% reduction with placebo (p<0.001). The most common adverse events were mild-to-moderate headache and dizziness, occurring in 12% and 9% of Nereus-treated subjects respectively, versus 7% and 5% in the control arm. No serious adverse events were attributed to Nereus, and the treatment demonstrated a half-life of approximately 8 hours, supporting once-daily dosing.
3. Market Reaction and Investor Impact
Following the approval announcement, Vanda Pharmaceuticals’ share price surged by 30% in U.S. trading on January 3, reflecting strong investor confidence in the commercial potential of Nereus. Trading volume increased fivefold relative to the 30-day average, indicating heightened market interest. Analysts at Morgan Bridge Capital and Horizon BioResearch revised their revenue forecasts, projecting Nereus global peak sales of $800 million to $1.1 billion by 2030, driven by broad adoption in cruise, aviation, and recreational travel markets.
4. Expansion Opportunities in GLP-1–Associated Nausea
Beyond motion sickness, Vanda has signaled plans to explore Nereus in clinical trials for the prevention of nausea and vomiting induced by GLP-1 receptor agonists, which are increasingly prescribed for weight-management and type 2 diabetes. Early phase II data presented at the October 2025 American Society for Clinical Pharmacology meeting showed a 58% reduction in patient-reported nausea scores over four weeks in a cohort of 120 GLP-1 users. If validated in larger studies, this indication could expand Nereus’s addressable patient population to over two million individuals in the United States alone.